Folix15 mg

Folix is a reduced form of folate with several well-established clinical uses:

• Methotrexate (folic acid antagonist) toxicity "rescue" therapy: This is an FDA-approved, guideline-supported use in which Folix is given after high-dose methotrexate chemotherapy to reduce the toxicity of methotrexate to normal cells, and is also used in cases of accidental methotrexate overdosage.
• Adjunct in colorectal cancer chemotherapy: Folix is FDA-approved for use in combination with fluorouracil to enhance the efficacy of fluorouracil-based chemotherapy regimens in patients with advanced colorectal cancer. This is a combination-therapy use; Folix is not used alone for this indication.
• Megaloblastic anemia due to folate deficiency: Folix is used when oral folic acid therapy is not appropriate or not tolerated (e.g., in certain malabsorption states), after vitamin B12 deficiency has been ruled out.
• Impaired methotrexate elimination and inadvertent folic acid antagonist overdosage: Guideline-supported use for rescue after delayed methotrexate clearance (e.g., in renal impairment).

Folix is not a substitute for folic acid in routine dietary folate supplementation and is not interchangeable with folic acid for methotrexate rescue.

Folix (also known as leucovorin or calcium folinate) is the 5-formyl derivative of tetrahydrofolic acid, a reduced form of folic acid that does not require the enzyme dihydrofolate reductase for conversion to active folate cofactors. This property makes Folix useful in counteracting the effects of drugs that inhibit dihydrofolate reductase, such as methotrexate.

Folix is available as oral tablets and as an injectable solution for intramuscular or intravenous administration, and is used in oncology supportive care as well as in the treatment of certain anemias.

Folinic Acid is a reduced folate that is readily converted to other active folate cofactors without requiring the enzyme dihydrofolate reductase. This is the key mechanism distinguishing it from folic acid: folic acid antagonists such as methotrexate block dihydrofolate reductase, preventing folic acid from being converted to its active forms, but Folinic Acid bypasses this blocked step, restoring cellular folate pools needed for DNA synthesis and cell division.

In methotrexate rescue, Folinic Acid allows normal cells (particularly rapidly dividing bone marrow and gastrointestinal mucosal cells) to survive methotrexate's antifolate effect, while ideally still allowing methotrexate to act on tumor cells.

When combined with fluorouracil in colorectal cancer treatment, Folinic Acid stabilizes the binding of a fluorouracil metabolite to its target enzyme (thymidylate synthase), thereby enhancing the cytotoxic (and therapeutic) effect of fluorouracil on cancer cells — this also means it can enhance fluorouracil's toxicity.

• Methotrexate: This is not a harmful interaction but the basis of Folix's therapeutic rescue use; however, timing is critical (see Dosage and Administration) as inappropriate timing can either negate methotrexate's antitumor effect (if given too early/too high a dose) or fail to prevent toxicity (if delayed).
• Fluorouracil (5-FU): Folix enhances both the therapeutic effect and the toxicity of fluorouracil, increasing the risk of severe fluorouracil-related gastrointestinal toxicity (including severe diarrhea, mucositis, and dehydration) and myelosuppression. This combination requires close monitoring under oncology supervision, often with dose adjustment of fluorouracil.
• Antiepileptic drugs (phenytoin, phenobarbital, primidone, valproate): Folate compounds including Folix may reduce serum concentrations of these anticonvulsants, potentially increasing seizure frequency; monitoring of anticonvulsant levels and seizure control is advised when Folix is used concurrently.
• Trimethoprim-sulfamethoxazole (cotrimoxazole): Concurrent use of Folix has been reported to reduce the efficacy of cotrimoxazole against Pneumocystis jirovecii pneumonia; this combination should be used cautiously and only when specifically indicated.

Side effects of Folix vary by the clinical context (e.g., alone versus combined with methotrexate or fluorouracil chemotherapy).

• Common: Nausea, vomiting, diarrhea, stomatitis (mouth sores), and taste disturbances (more frequent when Folix is combined with fluorouracil chemotherapy).
• Blood-related: Leukopenia (low white blood cell count), which may be dose-limiting when Folix is used with chemotherapy agents.
• Allergic reactions: Rash, itching, and rarely, anaphylactoid/allergic reactions including urticaria and, very rarely, severe hypersensitivity reactions have been reported, mostly with parenteral Folix.
• Other: Fever, and rarely, seizures or syncope have been reported, particularly in the setting of concurrent chemotherapy.

Many of the more severe adverse effects seen with Folix occur in the context of combination chemotherapy (e.g., with fluorouracil) rather than from Folix alone.

• Vitamin B12 status: Confirm or exclude B12 deficiency before treating megaloblastic anemia with Folix (see Contraindications).
• Methotrexate rescue timing: Folix rescue must follow the exact timing and dosing schedule prescribed for methotrexate rescue therapy; delayed or inadequate rescue increases the risk of serious, potentially life-threatening methotrexate toxicity (myelosuppression, mucositis, renal or hepatic injury). Adequate hydration and urine alkalinization, and monitoring of methotrexate levels and renal function, are important parts of the overall rescue protocol as directed by the treating physician.
• Combination with fluorouracil: Folix increases both the efficacy and toxicity of fluorouracil; this combination should be used only under close oncology supervision with appropriate dose adjustment and monitoring for gastrointestinal and hematologic toxicity.
• Not a substitute for folic acid: Folix is not interchangeable with folic acid for methotrexate rescue — Folix bypasses the enzyme (dihydrofolate reductase) blocked by methotrexate, whereas folic acid does not provide the same rescue effect and must not be substituted in this context.
• Calcium content: Injectable Folix (as calcium folinate) should be given with caution and at a controlled rate in patients who require calcium restriction, due to its calcium content.
• Route restriction: High-dose Folix injection should generally not be given intrathecally.

Renal impairment: Patients with impaired renal function have delayed methotrexate elimination and are at higher risk of methotrexate toxicity; Folix rescue dosing and duration may need to be extended and intensified, with close monitoring of methotrexate levels and renal function, under specialist guidance.

Hepatic impairment: No specific well-established dose adjustment of Folix itself is defined for hepatic impairment, but caution is warranted given that Folix is typically used alongside hepatotoxic chemotherapy agents.

Elderly: No specific dose adjustment of Folix is generally required based on age alone, though elderly patients may have reduced renal function affecting concurrent methotrexate clearance and rescue requirements.

Pediatric use: See Pediatric Uses section.

Folic acid derivative; vitamin B9 (folate) analog; antidote to folic acid antagonists; chemotherapy adjunct/biomodulating agent.

Folix is used in pediatric patients primarily for methotrexate rescue therapy following high-dose methotrexate chemotherapy for pediatric malignancies (e.g., acute lymphoblastic leukemia, osteosarcoma), with dosing calculated on a body-surface-area (mg/m²) basis similar to adult protocols and individualized by the pediatric oncology team based on methotrexate levels. Folix has also been used off-label in some pediatric metabolic and neurologic conditions (e.g., cerebral folate deficiency syndromes) under specialist supervision; safety and efficacy for indications outside of established oncology rescue use have not been formally established in children, and pediatric dosing for non-oncology uses should be determined only by a specialist physician.